Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Respir Med
; 145: 130-137, 2018 12.
Article
em En
| MEDLINE
| ID: mdl-30509701
ABSTRACT
INTRODUCTION:
The cost-effectiveness of long-acting muscarinic antagonist (LAMA) umeclidinium bromide (UMEC) 62.5⯵g as add-on therapy to other maintenance COPD treatments is unknown.METHODS:
This analysis assessed the cost-effectiveness of the following in COPD UMEC + fluticasone furoate/vilanterol 100/25 µg (FF/VI); UMEC + fluticasone propionate/salmeterol 250/50 µg (FP/SAL); and UMEC + several alternative choices of inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA). The model was informed with direct and indirect data from previously published studies, with a UK perspective and a lifetime horizon. Sensitivity analyses were also performed.RESULTS:
For the lifetime horizon, compared with FF/VI, FP/SAL and ICS/LABAs, addition of UMEC was associated with incremental costs per quality-adjusted life-years (QALY) of £4050, £7210 and £5780, respectively, and incremental costs per life year gain of £3380, £6020 and £4940. All UMEC-containing regimens resulted in numerically lower exacerbation rates versus comparator regimens over a lifetime horizon.CONCLUSIONS:
Addition of UMEC to various ICS/LABA treatments was associated with higher cost than ICS/LABA alone, but was cost-effective in most scenarios.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinuclidinas
/
Análise Custo-Benefício
/
Antagonistas Muscarínicos
/
Doença Pulmonar Obstrutiva Crônica
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article